Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 63 articles:
HTML format
Text format



Single Articles


    January 2018
  1. FAURE F, Jouve M, Lebhar-Peguillet I, Sadaka C, et al
    Blood monocytes sample MelanA/MART1 antigen for long-lasting cross-presentation to CD8(+) T cells after differentiation into dendritic cells.
    Int J Cancer. 2018;142:133-144.
    PubMed     Text format     Abstract available


    December 2017
  2. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Text format     Abstract available


  3. GALLAGHER SJ, Gunatilake D, Beaumont KA, Sharp DM, et al
    HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31199.
    PubMed     Text format     Abstract available


  4. HUANG L, Qin Y, Zuo Q, Bhatnagar K, et al
    Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
    Int J Cancer. 2017 Dec 6. doi: 10.1002/ijc.31196.
    PubMed     Text format     Abstract available


    November 2017
  5. CHEN ST, Li X, Han J
    Personal history of non-melanoma skin cancer diagnosis and death from melanoma in women.
    Int J Cancer. 2017 Nov 24. doi: 10.1002/ijc.31176.
    PubMed     Text format     Abstract available


  6. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Reply to prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 20. doi: 10.1002/ijc.31162.
    PubMed     Text format    


  7. KAWADA T
    Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study.
    Int J Cancer. 2017 Nov 18. doi: 10.1002/ijc.31163.
    PubMed     Text format    


  8. AITKEN JF, Youlden DR, Baade PD, Soyer HP, et al
    Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.
    Int J Cancer. 2017 Nov 6. doi: 10.1002/ijc.31141.
    PubMed     Text format     Abstract available


    October 2017
  9. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and cutaneous melanoma: Prospective data from the population-based Janus Cohort.
    Int J Cancer. 2017 Oct 6. doi: 10.1002/ijc.31086.
    PubMed     Text format     Abstract available


  10. SANTOS JM, Havunen R, Siurala M, Cervera-Carrascon V, et al
    Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.
    Int J Cancer. 2017;141:1458-1468.
    PubMed     Text format     Abstract available


    September 2017
  11. BOADA A, Tejera-Vaquerizo A, Ribero S, Puig S, et al
    Sentinel Lymph Node Biopsy vs Observation in Thick Melanoma: A Multicenter Propensity Score Matching Study.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31078.
    PubMed     Text format     Abstract available


  12. GABELLINI C, Gomez-Abenza E, Ibanez-Molero S, Tupone MG, et al
    Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model.
    Int J Cancer. 2017 Sep 26. doi: 10.1002/ijc.31075.
    PubMed     Text format     Abstract available


  13. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    PubMed     Text format     Abstract available


    August 2017
  14. UTJES D, Lyth J, Lapins J, Eriksson H, et al
    Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas - a nationwide, population-based study.
    Int J Cancer. 2017 Aug 11. doi: 10.1002/ijc.30925.
    PubMed     Text format     Abstract available


    July 2017
  15. BOTTERI E, Stoer NC, Sakshaug S, Graff-Iversen S, et al
    Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
    Int J Cancer. 2017 Jul 7. doi: 10.1002/ijc.30878.
    PubMed     Text format     Abstract available


  16. KOU Y, Ji L, Wang H, Wang W, et al
    Connexin 43 Upregulation by Dioscin Inhibits Melanoma Progression via Suppressing Malignancy and Inducing M1 Polarization.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30872.
    PubMed     Text format     Abstract available


    June 2017
  17. GORDON D, Hansson J, Eloranta S, Gordon M, et al
    Primary tumor sites in relation to ultraviolet radiation exposure and skin visibility correlate with survival in cutaneous melanoma.
    Int J Cancer. 2017 Jun 20. doi: 10.1002/ijc.30843.
    PubMed     Text format     Abstract available


  18. LAURENZANA A, Chilla A, Luciani C, Peppicelli S, et al
    uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30817.
    PubMed     Text format     Abstract available


  19. TU YN, Tong WL, Samy MD, Yavorski JM, et al
    Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-alpha/beta V(D)J recombinations correlates with PD-1 expression.
    Int J Cancer. 2017;140:2568-2576.
    PubMed     Text format     Abstract available


    May 2017
  20. LI X, Liu H, Amos CI, Lee JE, et al
    A PGC1beta genetic variant associated with nevus count and melanoma mortality.
    Int J Cancer. 2017 May 23. doi: 10.1002/ijc.30802.
    PubMed     Text format    


  21. LIU S, Wang Y, Xue W, Liu H, et al
    Genetic Variants in the Genes Encoding Rho GTPases and Related Regulators Predict Cutaneous Melanoma-specific Survival.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30785.
    PubMed     Text format     Abstract available


    March 2017
  22. TANG JQ, Hou XY, Yang CS, Li YX, et al
    Recent developments in nanomedicine for melanoma treatment.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30708.
    PubMed     Text format     Abstract available


  23. SHI H, Zhang J, Han X, Li H, et al
    Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression.
    Int J Cancer. 2017;140:1370-1383.
    PubMed     Text format     Abstract available


  24. SILVERSMIT G, Jegou D, Vaes E, Van Hoof E, et al
    Cure of cancer for seven cancer sites in the Flemish Region.
    Int J Cancer. 2017;140:1102-1110.
    PubMed     Text format     Abstract available


    February 2017
  25. CAINI S, Masala G, Saieva C, Kvaskoff M, et al
    Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.
    Int J Cancer. 2017 Feb 20. doi: 10.1002/ijc.30659.
    PubMed     Text format     Abstract available


  26. DE VRIES E, Amador JR, Rincon CJ, Uribe C, et al
    Cutaneous Melanoma Attributable to Solar Radiation in Cali, Colombia.
    Int J Cancer. 2017 Feb 10. doi: 10.1002/ijc.30638.
    PubMed     Text format     Abstract available


  27. PARK SM, Li T, Wu S, Li WQ, et al
    Niacin intake and risk of skin cancer in US women and men.
    Int J Cancer. 2017 Feb 2. doi: 10.1002/ijc.30630.
    PubMed     Text format     Abstract available


    January 2017
  28. OUDE OPHUIS CM, Louwman MW, Grunhagen DJ, Verhoef C, et al
    Implementation of the 7th Edition AJCC Staging System: Effects on Staging and Survival for pT1 Melanoma. A Dutch Population Based Study.
    Int J Cancer. 2017 Jan 20. doi: 10.1002/ijc.30607.
    PubMed     Text format     Abstract available


  29. POTRONY M, Rebollo-Morell A, Gimenez-Xavier P, Zimmer L, et al
    IRF4 rs12203592 functional variant and melanoma survival.
    Int J Cancer. 2017 Jan 19. doi: 10.1002/ijc.30605.
    PubMed     Text format     Abstract available


  30. SIMOES RL, De-Brito NM, Cunha-Costa H, Morandi V, et al
    Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression.
    Int J Cancer. 2017;140:346-357.
    PubMed     Text format     Abstract available


    December 2016
  31. SHEN J, Song R, Wan J, Huff C, et al
    Global methylation of blood leukocyte DNA and risk of melanoma.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30577.
    PubMed     Text format     Abstract available


  32. BAUM C, Weiss C, Gebhardt C, Utikal J, et al
    Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas.
    Int J Cancer. 2016 Dec 9. doi: 10.1002/ijc.30563.
    PubMed     Text format     Abstract available


  33. LI H, Wang Y, Liu H, Shi Q, et al
    Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival.
    Int J Cancer. 2016 Dec 3. doi: 10.1002/ijc.30545.
    PubMed     Text format     Abstract available


    November 2016
  34. LAURILA JP, Laukkanen MO, Joensuu H, Salmi M, et al
    Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Int J Cancer. 2016;139:2270-6.
    PubMed     Text format     Abstract available


  35. HEGEDUS L, Garay T, Molnar E, Varga K, et al
    The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.
    Int J Cancer. 2016 Nov 4. doi: 10.1002/ijc.30503.
    PubMed     Text format     Abstract available


  36. DESCH A, Gebhardt C, Utikal J, Schneider SW, et al
    D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30498.
    PubMed     Text format     Abstract available


    September 2016
  37. SARRABAYROUSE G, Pich C, Teiti I, Tilkin-Mariame AF, et al
    Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30422.
    PubMed     Text format     Abstract available


    August 2016
  38. ZHANG W, Liu H, Yin J, Wu W, et al
    Genetic Variants in the PIWI-piRNA Pathway Gene DCP1A Predict Melanoma Disease-specific Survival.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30409.
    PubMed     Text format     Abstract available


  39. ROCKBERG J, Amelio JM, Taylor A, Jorgensen L, et al
    Epidemiology of cutaneous melanoma in Sweden - stage specific survival and rate of recurrence.
    Int J Cancer. 2016 Aug 26. doi: 10.1002/ijc.30407.
    PubMed     Text format     Abstract available


    June 2016
  40. VAYSSE A, Fang S, Brossard M, Wei Q, et al
    A comprehensive genome-wide analysis of melanoma Breslow thickness identifies interaction between CDC42 and SCIN genetic variants.
    Int J Cancer. 2016 Jun 27. doi: 10.1002/ijc.30245.
    PubMed     Text format     Abstract available


  41. MAXWELL R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, et al
    BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Int J Cancer. 2016 Jun 25. doi: 10.1002/ijc.30241.
    PubMed     Text format     Abstract available


  42. MIRZAEI H, Naseri G, Rezaee R, Mohammadi M, et al
    Curcumin: A new candidate for melanoma therapy?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30224.
    PubMed     Text format     Abstract available


  43. GANDINI S, Ferrucci PF, Botteri E, Tosti G, et al
    Prognostic significance of hematological profiles in melanoma patients.
    Int J Cancer. 2016 Jun 2. doi: 10.1002/ijc.30215.
    PubMed     Text format     Abstract available


    May 2016
  44. ORTEGA-MARTINEZ I, Gardeazabal J, Erramuzpe A, Sanchez-Diez A, et al
    Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I-II early stage melanoma.
    Int J Cancer. 2016 May 23. doi: 10.1002/ijc.30202.
    PubMed     Text format     Abstract available


  45. POTRONY M, Carreras E, Aranda F, Zimmer L, et al
    Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30184.
    PubMed     Text format     Abstract available


    April 2016
  46. TAYLOR NJ, Thomas NE, Anton-Culver H, Armstrong BK, et al
    Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma.
    Int J Cancer. 2016 Apr 22. doi: 10.1002/ijc.30157.
    PubMed     Text format     Abstract available


  47. SMALLEY KS, Fedorenko IV, Kenchappa R, Sahebjam S, et al
    Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.
    Int J Cancer. 2016 Apr 15. doi: 10.1002/ijc.30147.
    PubMed     Text format     Abstract available


  48. ANDZINSKI L, Kasnitz N, Stahnke S, Wu CF, et al
    Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.
    Int J Cancer. 2016;138:1982-93.
    PubMed     Text format     Abstract available


    March 2016
  49. SIMBERG-DANELL C, Lyth J, Mansson-Brahme E, Frohm-Nilsson M, et al
    Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden.
    Int J Cancer. 2016 Mar 23. doi: 10.1002/ijc.30103.
    PubMed     Text format     Abstract available


  50. ROWE CJ, Tang F, Hughes MC, Rodero MP, et al
    Molecular markers to complement sentinel node status in predicting survival in patients with high risk locally invasive melanoma.
    Int J Cancer. 2016 Mar 14. doi: 10.1002/ijc.30085.
    PubMed     Text format     Abstract available


    February 2016
  51. NAGORE E, Heidenreich B, Rachakonda S, Garcia-Casado Z, et al
    TERT promoter mutations in melanoma survival.
    Int J Cancer. 2016 Feb 13. doi: 10.1002/ijc.30042.
    PubMed     Text format     Abstract available


  52. DEVARAPU SK, Mamidi S, Ploger F, Dill O, et al
    Cytotoxic Activity Against Human Neuroblastoma and Melanoma Cells Mediated by IgM Antibodies Derived from Peripheral Blood of Healthy Donors.
    Int J Cancer. 2016 Feb 2. doi: 10.1002/ijc.30025.
    PubMed     Text format     Abstract available


    January 2016
  53. ERIKSSON H, Lyth J, Andersson TM
    The proportion cured of patients diagnosed with stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study.
    Int J Cancer. 2016 Jan 27. doi: 10.1002/ijc.30023.
    PubMed     Text format     Abstract available


    December 2015
  54. OROUJI E, Orouji A, Gaiser T, Larribere L, et al
    MAP Kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.
    Int J Cancer. 2015 Dec 18. doi: 10.1002/ijc.29970.
    PubMed     Text format     Abstract available


  55. THOMSEN FB, Folkvaljon Y, Garmo H, Robinson D, et al
    Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study.
    Int J Cancer. 2015 Dec 14. doi: 10.1002/ijc.29961.
    PubMed     Text format     Abstract available


    September 2015
  56. LERRO CC, Koutros S, Andreotti G, Hines CJ, et al
    Use of acetochlor and cancer incidence in the Agricultural Health Study.
    Int J Cancer. 2015;137:1167-75.
    PubMed     Text format     Abstract available


    August 2015
  57. WISTUBA-HAMPRECHT K, Di Benedetto S, Schilling B, Sucker A, et al
    Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma.
    Int J Cancer. 2015 Aug 27. doi: 10.1002/ijc.29818.
    PubMed     Text format     Abstract available


  58. CORREA D, Somoza RA, Lin P, Schiemann WP, et al
    Mesenchymal Stem Cells regulate Melanoma Cancer Cells extravasation to bone and liver at their perivascular niche.
    Int J Cancer. 2015 Aug 1. doi: 10.1002/ijc.29709.
    PubMed     Text format     Abstract available


  59. AL-AHMADY ZS, Scudamore CL, Kostarelos K
    Triggered doxorubicin release in solid tumors from thermosensitive liposome-peptide hybrids: Critical parameters and therapeutic efficacy.
    Int J Cancer. 2015;137:731-43.
    PubMed     Text format     Abstract available


    June 2015
  60. RIBERO S, Davies JR, Glass D, Quaglino P, et al
    RE:RE: High naevus counts confer a favorable prognosis in melanoma patients.
    Int J Cancer. 2015 Jun 24. doi: 10.1002/ijc.29652.
    PubMed     Text format    


  61. AUTIER P, Funck-Brentano E, Aegerter P, Boniol M, et al
    Re: High nevus counts confer a favorable prognosis in melanoma patients by S Ribero and co-workers, published in the International Journal of Cancer, 2015 (Online 21 March 2015).
    Int J Cancer. 2015 Jun 20. doi: 10.1002/ijc.29648.
    PubMed     Text format    


    May 2015
  62. WAGNER NB, Weide B, Reith M, Tarnanidis K, et al
    Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.
    Int J Cancer. 2015 May 27. doi: 10.1002/ijc.29619.
    PubMed     Text format     Abstract available


  63. WALLINGFORD SC, Iannacone MR, Youlden DR, Baade PD, et al
    Comparison of melanoma incidence and trends among youth under 25 years in Australia and England, 1990-2010.
    Int J Cancer. 2015 May 8. doi: 10.1002/ijc.29598.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: